QRLBIO001 is an autologous live cell based therapy product for the treatment of chronic non-healing wounds. Our therapy is designed to be most potent in healing chronic wounds such as diabetic foot ulcers, venous leg ulcers, and any skin ulcers.
WELCOME TO QRL Bioscience Private Limited
Diabetic foot is one of the most serious and devastating complications of diabetes, which is characterized by ulceration of the lower limb with neuropathy and/or peripheral arterial disease.
Diabetic foot ulcer and non-healing chronic wounds are major health problems, which occurs in around 15% of the diabetes patients due to impaired wound healing and persistent inflammatory response. The condition is more frequent in older patients. It is also the major cause of diabetes associated amputation, which requires prolonged hospitalization and clinical management. Mortality following amputation is 50% and amputee also lose the contralateral limb within 5 years, adversely affecting the quality of life. Early recognition and treatment of foot ulcers in diabetic patient is critical for the successful outcome of the treatment.
Venous leg ulcers are chronic non-healing leg ulcers caused by insufficient blood flow in the lower part of the leg veins. The symptoms of a venous leg ulcer include pain, itching and swelling in the affected leg with discoloured skin around the ulcer.
The non-healing nature of non-healing wounds are due to the inherent dysregulated cellular function and their inability to promote healing at the site of wound. QRL has developed a novel Cell based therapy for treating any chronic non-healing ulcers. QRL has developed this technology through its own research on novel cells for promoting wound healing.
Collaborations
